Olabir Tablets — Olaparib 150 mg (120 Tablets) Aprazer
Olabir 150 mg (Olaparib) is an innovative targeted anticancer medication and a first-in-class inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes. The mechanism of action involves blocking PARP enzymes, which are essential for DNA repair in cells. In cancer cells with BRCA1/2 gene mutations, DNA repair pathways are already compromised; PARP inhibition leads to the accumulation of critical DNA damage and subsequent cell death (synthetic lethality), while healthy tissues remain largely unaffected.
Manufacturer: Aprazer. This medicinal product is a high-quality generic of the innovator drug Lynparza. It is manufactured in advanced pharmaceutical facilities in compliance with international quality standards, ensuring full bioequivalence and an identical clinical safety profile to the brand-name medication.
Key Features:
- ✅ Targeted Action: Selectively targets tumor cells with deficiencies in DNA repair mechanisms (BRCA-associated tumors).
- ✅ Proven Clinical Efficacy: Significantly extends progression-free survival across multiple types of solid tumors.
- ✅ Convenient Regimen: Oral tablet form allows for long-term maintenance therapy in an outpatient setting.
Olabir is prescribed by an oncologist (as monotherapy or in combination therapy) for patients with specific genetic markers:
- 🔹 Ovarian cancer (including fallopian tube or primary peritoneal cancer) — maintenance treatment following chemotherapy.
- 🔹 Breast cancer (metastatic, HER2-negative, with germline BRCA mutation).
- 🔹 Prostate cancer (metastatic castration-resistant prostate cancer with HRR gene mutations).
- 🔹 Pancreatic adenocarcinoma (metastatic, with germline BRCA mutation).
Sales Unit: 1 pack containing 120 tablets, each with 150 mg of Olaparib.
⚠️ APPLICATION INSTRUCTIONS:
- Dosage: The standard recommended dose is 300 mg (two 150 mg tablets) taken twice daily (total daily dose of 600 mg).
- Method: Swallow tablets whole. May be taken with or without food.
- Duration: Treatment continues until disease progression or unacceptable toxicity occurs.
- Storage: Store in the original package below 30°C in a dry place.
- ⛔ Pregnancy and Breastfeeding: Olaparib is highly hazardous to the fetus. It is strictly contraindicated during pregnancy and lactation.
- ⛔ Renal Impairment: Severe renal impairment or end-stage renal disease requiring dialysis.
- Hypersensitivity to Olaparib or any of its excipients.
- Pediatric use (safety and efficacy in children under 18 have not been established).
Treatment requires regular medical supervision. Potential side effects include:
- 🩸 Hematologic: Anemia, neutropenia, and leukopenia.
- 🤢 Gastrointestinal: Nausea, vomiting, diarrhea, and decreased appetite.
- 🏃♂️ General: Fatigue (asthenia), dizziness, and taste disturbances (dysgeusia).
- 🩺 Lab findings: Increased blood creatinine levels.
Pack size
What Customers Say
No reviews yet
Your review can be the first!